Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution” - 19/04/20
Doi : 10.1016/j.jaad.2020.03.103
Mark Lebwohl, MD a, Ryan Rivera-Oyola, MS a, ⁎ 
, Dedee F. Murrell, MA, BMBCh, MD, FRCP, FACD b
, Dedee F. Murrell, MA, BMBCh, MD, FRCP, FACD b a Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mt Sinai Hospital, New York, New York
b Department of Dermatology, St. George Hospital, University of New South Wales, Sydney, Australia
∗Correspondence to: Ryan Rivera-Oyola, The Kimberly and Eric J. Waldman Department of Dermatology, 5 E 98th St, 5th Floor, New York, NY, 10029The Kimberly and Eric J. Waldman Department of Dermatology5 E 98th St, 5th FloorNew YorkNY10029
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Sunday 19 April 2020
El texto completo de este artículo está disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Lebwohl is an employee of Mount Sinai, receives research funds from AbbVie, Amgen, Eli Lilly, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, and UCB, Inc, and has been the principal investigator for numerous clinical trials but has no personal financial gain. Dr Murrell is an employee of St George Hospital, has been an investigator/advisor for Novartis, Sun Pharma, Janssen and AbbVie, and is also the director of a clinical trial center for dermatologic diseases. Ryan Rivera-Oyola has no relevant conflicts of interest. |
|
| IRB approval status: Not applicable. |
© 2020
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.